[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100573679":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":31,"responsibleParty":52,"collaborators":20,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":20,"eligibilityCriteria":62,"healthyVolunteers":63,"sex":64,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":20,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":20,"overallStatus":33,"whyStopped":20,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"University of Iowa","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"High-salt supplement","EXPERIMENTAL","Participants will be counseled to consume a low-salt diet (\\\u003C2000 mg\u002Fday of sodium) for 10 days. After 3 days of a low-salt diet, participants will consume the high-salt supplement (4500 mg\u002Fday) for 7 days while maintaining a low-salt diet. On days 3 and 10, participants will arrive at the laboratory where the investigators will assess microvascular endothelial function. Blood will be collected to investigate circulating angiotensin II responses to low- (day 3) and high- (day 10) salt diet. On days 2 and 9, participants will undergo ambulatory blood pressure monitoring and 24-hour urine collection.",[13],"Drug: Eplerenone",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Eplerenone","Local heating: eplerenone is locally and acutely delivered to the cutaneous microvasculature during local heating of the skin to assess endothelium-dependent dilation, L-NAME is added to assess nitric oxide-dependent dilation during this response.",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Anna Reid-Stanhewicz, PhD","PRINCIPAL_INVESTIGATOR",[26],{"name":27,"role":28,"phone":29,"phoneExt":20,"email":30},"Kelsey Schwartz, PhD","CONTACT","319-467-1732","kelsey-schwartz@uiowa.edu",[32],{"facility":5,"status":33,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"RECRUITING","Iowa City","Iowa","52242","United States","US",{"type":40,"coordinates":41},"Point",[42,43],-91.53017,41.66113,{"lat":43,"lon":42},[46,47,51],{"name":27,"role":28,"phone":29,"phoneExt":20,"email":30},{"name":48,"role":28,"phone":49,"phoneExt":20,"email":50},"Claire Goebel","319-335-1914","claire-goebel@uiowa.edu",{"name":23,"role":24,"phone":20,"phoneExt":20,"email":20},{"type":53,"investigatorFullName":54,"investigatorTitle":55,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"SPONSOR_INVESTIGATOR","Anna Stanhewicz, PhD","Assistant Professor","100573679","early-phase-1-vascular-effects-of-high-salt-after-preeclampsia-100573679",false,"NCT06749418","Vascular Effects of High-Salt After Preeclampsia","Role of the Mineralocorticoid Receptor in Microvascular Endothelial Dysfunction After Preeclampsia","Inclusion Criteria:\n\n* women who had preeclampsia and women who did not have preeclampsia\n* 12 weeks to 5 years postpartum\n* 18-45 years old\n\nExclusion Criteria:\n\n* history of hypertension or metabolic disease before pregnancy\n* history of gestational diabetes\n* history of gestational hypertension without preeclampsia\n* skin diseases\n* current tobacco use\n* current antihypertensive medication\n* statin or other cholesterol-lowering medication\n* currently pregnant\n* body mass index less than 18.5 kg\u002Fm2\n* allergy to materials used during the experiment.(e.g. latex),\n* known allergy to study drugs or salt-supplement",true,"FEMALE","18 Years","45 Years",{"count":68,"type":69},40,"ESTIMATED","INTERVENTIONAL",[72],"EARLY_PHASE1","Women who develop preeclampsia during pregnancy are more likely to develop and die of cardiovascular disease later in life, even if they are otherwise healthy. Importantly, women who had preeclampsia have an exaggerated vascular responsiveness to hypertensive stimuli, such as high-salt intake, compared to women who had a healthy pregnancy. The reason why this occurs is unclear but may be related to impaired endothelial function and dysregulation of the angiotensin system that occurs during the preeclamptic pregnancy and persists postpartum, despite the remission of clinical symptoms. While the association between a history of preeclampsia and vascular dysfunction leading to elevated CVD risk is well known, the mechanisms underlying this dysfunction remains unclear.\n\nThe purpose of this study is to examine the role of vascular mineralocorticoid receptor, the terminal receptor in the angiotensin system that contributes to blood pressure regulation, in mediating exaggerated microvascular endothelial dysfunction before and after a high-salt stimulus. This will help us better understand the mechanisms of microvascular dysfunction these women, and how inhibition of these receptors may improve microvascular function.\n\nIn this study, we use the blood vessels in the skin as a representative vascular bed for examining mechanisms of microvascular dysfunction in humans. Using a minimally invasive technique (intradermal microdialysis for the local delivery of pharmaceutical agents) we examine the blood vessels in a nickel-sized area of the skin.",[75,76],"Preeclampsia","Preeclampsia Postpartum","2026-02-10",{"date":79,"type":80},"2026-02-13","ACTUAL",{"date":82,"type":80},"2025-01-02",{"date":84,"type":69},"2027-11-15",{"name":54,"class":6},1]